Rosuvastatin Side Effects

Common / General

• Headache, dizziness
• GI upset - nausea, abdominal pain, constipation
• Myalgia / generalized muscle aches - the most frequently reported complaint, even without lab abnormalities

Muscle-related (most clinically important)

• Myopathy - muscle pain, tenderness, or weakness, sometimes with elevated creatine kinase (CK)
• Rhabdomyolysis - rare but serious breakdown of muscle tissue that can cause myoglobinuria and acute kidney injury. Risk is dose-dependent and increases with drug interactions (e.g., cyclosporine, gemfibrozil, protease inhibitors) that raise rosuvastatin plasma levels (Goodman & Gilman's Pharmacological Basis of Therapeutics)
• Mechanistically linked to statins' inhibition of ubiquinone (CoQ10) and heme A synthesis, which impairs mitochondrial oxidative phosphorylation in muscle - Lippincott Illustrated Reviews: Biochemistry, 8th ed.

Hepatic

• Elevated liver transaminases - generally mild and reversible; routine liver enzyme monitoring is recommended, especially at higher doses or with hepatic risk factors

Renal

• Rosuvastatin can cause dose-related proteinuria and (rarely) hematuria, thought to be tubular in origin rather than glomerular damage; this is more notable with rosuvastatin than some other statins, particularly at the 40 mg dose

Metabolic

• New-onset hyperglycemia / increased risk of type 2 diabetes - a class effect seen with high-intensity statins, including rosuvastatin

Other/less common

• Tendon issues including rare reports of tendon rupture (statin class effect)
• Peripheral neuropathy (rare)
• Hypersensitivity reactions including rash

Drug interaction and pharmacogenetic risk factors

Practical monitoring points

• Baseline and as-needed liver function tests
• CK levels if a patient reports significant new muscle pain/weakness
• Renal function monitoring, particularly at higher doses
• Screen for and counsel on interacting drugs (fibrates, cyclosporine, certain antivirals/antifungals, high-dose niacin)

Atorvastatin vs Rosuvastatin

Potency / Efficacy

• LDL reduction: Atorvastatin ~51.5 mg/dL vs Rosuvastatin ~55.7 mg/dL
• HDL increase: Atorvastatin ~1.85 mg/dL vs Rosuvastatin ~3.87 mg/dL
• Triglyceride reduction: Atorvastatin ~24.8 mg/dL vs Rosuvastatin ~32.0 mg/dL

High-Intensity Dosing (per ACC/AHA-style intensity tables, Symptom to Diagnosis)

Pharmacokinetics

• Half-life: Both are notably long compared to other statins - about 20 hours each (vs 1-4 h for most others, ~12 h for simvastatin) - Goodman & Gilman's Pharmacological Basis of Therapeutics. This long half-life means both can be dosed at any time of day, unlike short-acting statins (simvastatin, lovastatin, fluvastatin, pravastatin) which are best taken in the evening to match nocturnal cholesterol synthesis.
• Metabolism: Atorvastatin is metabolized by CYP3A4, making it more prone to interactions with CYP3A4 inhibitors/inducers (e.g., clarithromycin, itraconazole, grapefruit juice, carbamazepine, cobicistat, conivaptan). Rosuvastatin undergoes minimal CYP metabolism and instead relies more on OATP1B1 (SLCO1B1) hepatic transport, so it interacts more through transporter-mediated pathways (e.g., cyclosporine significantly raises rosuvastatin levels).
• Absorption: Both are fluorine-containing, active-as-given compounds (not prodrugs), with variable oral absorption (40-75% class-wide) - Katzung's Basic and Clinical Pharmacology.

Drug Interactions

• Atorvastatin: more affected by CYP3A4 inhibitors/inducers - macrolides, azole antifungals, HIV protease inhibitors, cobicistat, conivaptan, carbamazepine.
• Rosuvastatin: more affected by OATP1B1 inhibitors (cyclosporine) and has fewer CYP3A4-mediated interactions, which some clinicians see as an advantage in patients on multiple CYP3A4-interacting drugs.
• Both increase myopathy/rhabdomyolysis risk with fibrates (especially gemfibrozil), and doses should be capped when combined.

Special Populations / Clinical Contexts

• In HIV patients on antiretroviral therapy, atorvastatin and rosuvastatin are preferred over pravastatin/fluvastatin because they lower LDL more effectively, though ART drug interactions must be checked case-by-case (Braunwald's Heart Disease).
• Both are used in secondary stroke prevention as high-intensity options (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) in patients under 75 without safety concerns (Washington Manual of Medical Therapeutics).
• Renal effects: rosuvastatin has a somewhat higher reported association with dose-related proteinuria at high doses (40 mg) compared to atorvastatin, related to how it's handled renally, though clinically significant renal impairment is uncommon.

Side Effect Profile

Bottom Line

• Choose rosuvastatin for slightly greater LDL/TG/HDL benefit per mg, fewer CYP3A4 interactions, and flexibility with dosing time.
• Choose atorvastatin when the patient is not on OATP1B1 inhibitors (e.g., cyclosporine), when a wider approved dose range is useful, or based on cost/formulary/insurance preference (atorvastatin is generic and often cheaper/more available).